Вивчення терапевтичного потенціалу метформіну при синдромі полікістозних яєчників: фокусування на гіперандрогенії на прикладі вибірки іракських жінок

Polycystic ovary syndrome (PCOS) is the most commonly diagnosed condition in women of reproductive age. This pathology may be linked to an intricate endocrine disorder, given its diverse nature and the unexplained circumstances surrounding its origins. The main clinical features of PCOS include reduced ovulation frequency, irregular menstrual cycles, decreased fertility, polycystic ovaries detected by ultrasound examination, and elevated levels of male hormones like testosterone, which causes excessive facial or body hair growth and acne.The objective: to examine the efficacy of metformin in diminishing hyperandrogenism and enhancing clinical outcomes in women diagnosed with PCOS.Materials and methods. A total of 55 women diagnosed with PCOS were included in the study. The participants had a mean age of 31.70 ± 7.79 years, with a range between 18 and 45 years old. The diagnosis of PCOS was made based on the Rotterdam criteria. The patients took metformin, tablets, 500 mg twice a day with two main meals for 3 months. Serum concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), total and free testosterone were determined before treatment and 3 months after treatment.Results. It was found that after taking metformin for 3 months, the concentrations of total testosterone and free testosterone significantly decreased compared to pre-treatment values (p < 0.0001). Similar changes were found in the levels of LH and FSH. Their values significantly decreased after 3 months of treatment compared to pre-treatment values (p < 0.0001).Conclusions. Metformin treatment of PCOS induced significant reduction in serum luteinizing hormone, FSH, testosterone concentrations in the PCOS patient after three months treatment duration.